Genzyme, a Sanofi company, announced today that Health Canada has approved Aubagio® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
"There are many patients who simply cannot tolerate injections and have had no simple, effective, once daily oral medication until now," said Dr. Mark Freedman, Director, Multiple Sclerosis Research Unit and Professor of Neurology and Senior Scientist at the University of Ottawa and Ottawa Hospital Research Institute. "As a new oral treatment option, Aubagio is an important advancement for the MS community and may help improve quality of life for people living with this debilitating disease........ " Read More - http://www.ms-uk.org/aubagio
Oral MS treatment Aubagio® approved for RRMS in Canada
Oral MS treatment Aubagio® approved for RRMS in Canada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1056 Views
-
Last post by frodo
-
- 0 Replies
- 1684 Views
-
Last post by NHE
-
- 0 Replies
- 689 Views
-
Last post by DIM
-
- 0 Replies
- 2458 Views
-
Last post by NHE
-
- 1 Replies
- 1138 Views
-
Last post by Petr75
-
- 5 Replies
- 2440 Views
-
Last post by Jaded
-
- 0 Replies
- 4417 Views
-
Last post by NHE
-
- 0 Replies
- 2176 Views
-
Last post by frodo
-
- 0 Replies
- 2480 Views
-
Last post by Cece